[Market Focus] Hyundai ADM: Research Poised to Overturn 80 Years of Cancer Treatment Failures... The Miracle of K-Biotech

Hyundai ADM has continued its upward trend for five consecutive days. The company's stock price appears to be influenced by the news that a research abstract on Penetrium (a niclosamide-based nanohybrid), a new drug candidate jointly developed with Hyundai Bioscience, has been officially accepted for poster presentation at the 'AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics 2025,' one of the world's most prestigious cancer conferences.

As of 9:24 a.m. on August 29, Hyundai ADM was trading at 3,125 won, up 125 won (4.17%) from the previous trading day.

Penetrium dismantles the tumor barrier by selectively removing only pathological CAFs while preserving normal fibroblasts. At the American Association for Cancer Research (AACR) 2025 held in Chicago in April, the company demonstrated in animal non-clinical models, including laboratory mice and companion dogs, that Penetrium addresses the "pseudo-resistance" phenomenon, which the academic community has identified as a cause of clinical failure. Hyundai ADM expects that the commercialization of Penetrium could significantly reduce the number of patients who die from metastatic cancer. Globally, annual cancer-related deaths exceed 10 million, with more than 90% attributed to metastatic cancer.

According to non-clinical data, including patient-derived organoid tests, Penetrium is potentially compatible with all existing anticancer drugs. In particular, it has been proven to be highly effective when used in combination with third-generation anticancer drugs, such as immunotherapy agents. When administered together with Anti-PD-1, a representative immunotherapy drug, metastatic biomarkers decreased by up to 96%, and the size of the primary tumor was reduced by 59.1%.

Hyundai ADM described Penetrium as a "first-in-class" anticancer therapy with a completely new mechanism that fundamentally addresses both the "diminished efficacy with repeated administration" and the "metastatic cancer" issues that have not been solved by conventional anticancer drugs for 80 years. When Penetrium is administered alongside existing anticancer drugs, it removes CAFs and normalizes the ECM, enabling simultaneous treatment of both primary and metastatic cancers, as well as prevention of cancer metastasis.

A Hyundai ADM official stated, "Cancer is no longer an unconquerable disease," adding, "Penetrium is an innovative new drug that not only treats primary and metastatic cancer simultaneously but also prevents cancer metastasis."

Jo Won-dong, CEO of Hyundai ADM, said, "The acceptance of this abstract represents global recognition of a new paradigm that can overcome the fundamental limitations of existing cancer therapies. Hyundai ADM, in cooperation with its parent company Hyundai Bioscience, will swiftly advance Penetrium into global clinical trials and commercialization, providing real treatment alternatives for patients with metastatic and refractory cancers, and delivering a paradigm shift in cancer therapy to our shareholders and society."

The efficacy of Penetrium has been demonstrated through mouse experiments, companion dog studies, and patient-derived pancreatic cancer organoid experiments. In a study where triple-negative breast cancer (TNBC) cells were implanted in mice, the combination of immunotherapy and Penetrium reduced the primary tumor by 59.07% and metastatic cancer by 96.06%. This was more effective than immunotherapy alone, which reduced the primary tumor by 22.04% and metastatic cancer by 69.26%.

In another experiment where non-small cell lung cancer (NSCLC) cells were implanted in mice, the group treated with bevacizumab alone showed a metastasis inhibition rate of 33%, while the group treated with both Penetrium and bevacizumab achieved a 100% metastasis inhibition rate.